Intrommune Therapeutics is a clinical-stage company that is tackling the global health burden caused by the expanding epidemic of food allergies. The company’s allergen exposure technology supports both prescription and consumer solutions that are safe, convenient, and effective for those at risk of, or living with, the life-threatening reality of food allergy. The product is a toothpaste that provides consistent exposure to allergenic proteins.